MEK/ERK pathway inhibitors as a treatment for inflammatory arthritis might result in the development of lupus: comment on the article by Thiel et al.
Sawalha
Amr H
AH
Richardson
Bruce
B
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D001169:Arthritis, Experimental / Q000188:drug therapy / Q000276:immunology*; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects; D004195:Disease Models, Animal; D007249:Inflammation / Q000188:drug therapy / Q000276:immunology; D008180:Lupus Erythematosus, Systemic / Q000209:etiology*; D051379:Mice; D020929:Mitogen-Activated Protein Kinase Kinases / Q000037:antagonists & inhibitors* / Q000276:immunology; D015398:Signal Transduction / Q000187:drug effects / Q000276:immunology*
D000893:Anti-Inflammatory Agents; D020929:Mitogen-Activated Protein Kinase Kinases